TY - JOUR
T1 - Anthracycline-Related Heart Failure
T2 - Certain Knowledge and Open Questions : Where Do we Stand with Chemotherapyinduced Cardiotoxicity?
AU - Robinson, Emma Louise
AU - Azodi, Maral
AU - Heymans, Stephane
AU - Heggermont, Ward
N1 - Funding Information:
E.L.R. and S.H. were supported by the CardioVasculair Onderzoek Nederland (CVON) EARLY-HFPEF consortium grant (Dutch Heart Foundation).
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12
Y1 - 2020/12
N2 - In the last decade, cardio-oncology has become a discipline on its own, with tremendous research going on to unravel the mechanisms underpinning different manifestations of cardiotoxicity caused by anticancer drugs. Although this domain is much broader than the effect of chemotherapy alone, a lot of questions about anthracycline-induced cardiotoxicity remain unknown. In this invited review, we provide insights in molecular mechanisms behind anthracycline-induced cardiotoxicity and put it in a clinical framework emphasizing the need for patients to understand, detect, and treat this detrimental condition.
AB - In the last decade, cardio-oncology has become a discipline on its own, with tremendous research going on to unravel the mechanisms underpinning different manifestations of cardiotoxicity caused by anticancer drugs. Although this domain is much broader than the effect of chemotherapy alone, a lot of questions about anthracycline-induced cardiotoxicity remain unknown. In this invited review, we provide insights in molecular mechanisms behind anthracycline-induced cardiotoxicity and put it in a clinical framework emphasizing the need for patients to understand, detect, and treat this detrimental condition.
U2 - 10.1007/s11897-020-00489-5
DO - 10.1007/s11897-020-00489-5
M3 - (Systematic) Review article
C2 - 32964378
SN - 1546-9530
VL - 17
SP - 357
EP - 364
JO - Current Heart Failure Reports
JF - Current Heart Failure Reports
IS - 6
ER -